Surrozen (Surrozen) Insider Ownership : 0.00 % (As of Jun. 09, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Surrozen Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Surrozen's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Surrozen's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Surrozen's Float Percentage Of Total Shares Outstanding is N/A.

Surrozen Insider Ownership Historical Data

The historical data trend for Surrozen's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen Insider Ownership Chart

Surrozen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Insider Ownership

Surrozen Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Insider Ownership	Get a 7-Day Free Trial										-	-	-	-	-

Surrozen Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Surrozen (Surrozen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZNW) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

SRZN:USA

Address

171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.surrozen.com

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).